Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: An open-label study

David G. Vossler; Joan A. Conry; Jerome V. Murphy; Rose Mary Boustany; Stella Legarda; Kevin Ruggles; Steven Schachter; Kaackuzhali Krishnamurthy; Raj Sheth; Blanca Vazquez; Greg Barkley; Harry Chugani; Michael Duchowny; Robert Flamini; Joseph Sirven; Basim Uthman; James Wheless; Jorge Asconape; C. Steve Miller; John Pellock; Cohn Van Orman; Francis Filloux

doi:10.1684/epd.2008.0168

Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: An open-label study

David G. Vossler, Joan A. Conry, Jerome V. Murphy, Rose Mary Boustany, Stella Legarda, Kevin Ruggles, Steven Schachter, Kaackuzhali Krishnamurthy, Raj Sheth, Blanca Vazquez, Greg Barkley, Harry Chugani, Michael Duchowny, Robert Flamini, Joseph Sirven, Basim Uthman, James Wheless, Jorge Asconape, C. Steve Miller, John PellockCohn Van Orman, Francis Filloux

Neurology

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Purpose. To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open-label setting. Methods. Thirty patients with refractory PME (aged ≥ 5 years), who were taking up to three antiepileptic drugs, received adjunctive zonisamide (≤ 6 mg/kg/day) therapy for 16 weeks. Myoclonic seizures were recorded daily over a 24-hour period or in 10-minute epochs in the morning, afternoon, and evening. Safety was assessed via adverse events (AEs); efficacy was measured by the percentage of patients experiencing a ≥ 50% decrease in myoclonic seizure frequency from baseline. Results. Treatment-related AEs, experienced by 53% (n = 16/30) of patients, led to five patients discontinuing zonisamide. The most common AEs were decreased appetite, somnolence, and asthenia. Overall, 36% of patients (n = 10/28) had a ≥ 50% reduction in myoclonic seizure frequency. Conclusions. These results suggest that zonisamide may be useful in the treatment of patients with PME. However, due to the size and open-label character of this study, further research is required.

Original language	English (US)
Pages (from-to)	31-34
Number of pages	4
Journal	Epileptic Disorders
Volume	10
Issue number	1
DOIs	https://doi.org/10.1684/epd.2008.0168
State	Published - Mar 2008

Keywords

Antiepileptic drug
Myoclonic seizures
Progressive myoclonic epilepsy
Zonisamide

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1684/epd.2008.0168

Cite this

Vossler, D. G., Conry, J. A., Murphy, J. V., Boustany, R. M., Legarda, S., Ruggles, K., Schachter, S., Krishnamurthy, K., Sheth, R., Vazquez, B., Barkley, G., Chugani, H., Duchowny, M., Flamini, R., Sirven, J., Uthman, B., Wheless, J., Asconape, J., Miller, C. S., ... Filloux, F. (2008). Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: An open-label study. Epileptic Disorders, 10(1), 31-34. https://doi.org/10.1684/epd.2008.0168

Vossler, DG, Conry, JA, Murphy, JV, Boustany, RM, Legarda, S, Ruggles, K, Schachter, S, Krishnamurthy, K, Sheth, R, Vazquez, B, Barkley, G, Chugani, H, Duchowny, M, Flamini, R, Sirven, J, Uthman, B, Wheless, J, Asconape, J, Miller, CS, Pellock, J, Van Orman, C & Filloux, F 2008, 'Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: An open-label study', Epileptic Disorders, vol. 10, no. 1, pp. 31-34. https://doi.org/10.1684/epd.2008.0168

@article{bde5b38312ed4f8c96f6051af2abbcec,

title = "Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: An open-label study",

abstract = "Purpose. To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open-label setting. Methods. Thirty patients with refractory PME (aged ≥ 5 years), who were taking up to three antiepileptic drugs, received adjunctive zonisamide (≤ 6 mg/kg/day) therapy for 16 weeks. Myoclonic seizures were recorded daily over a 24-hour period or in 10-minute epochs in the morning, afternoon, and evening. Safety was assessed via adverse events (AEs); efficacy was measured by the percentage of patients experiencing a ≥ 50% decrease in myoclonic seizure frequency from baseline. Results. Treatment-related AEs, experienced by 53% (n = 16/30) of patients, led to five patients discontinuing zonisamide. The most common AEs were decreased appetite, somnolence, and asthenia. Overall, 36% of patients (n = 10/28) had a ≥ 50% reduction in myoclonic seizure frequency. Conclusions. These results suggest that zonisamide may be useful in the treatment of patients with PME. However, due to the size and open-label character of this study, further research is required.",

keywords = "Antiepileptic drug, Myoclonic seizures, Progressive myoclonic epilepsy, Zonisamide",

author = "Vossler, {David G.} and Conry, {Joan A.} and Murphy, {Jerome V.} and Boustany, {Rose Mary} and Stella Legarda and Kevin Ruggles and Steven Schachter and Kaackuzhali Krishnamurthy and Raj Sheth and Blanca Vazquez and Greg Barkley and Harry Chugani and Michael Duchowny and Robert Flamini and Joseph Sirven and Basim Uthman and James Wheless and Jorge Asconape and Miller, {C. Steve} and John Pellock and {Van Orman}, Cohn and Francis Filloux",

year = "2008",

month = mar,

doi = "10.1684/epd.2008.0168",

language = "English (US)",

volume = "10",

pages = "31--34",

journal = "Epileptic Disorders",

issn = "1294-9361",

publisher = "Springer Paris",

number = "1",

}

TY - JOUR

T1 - Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy

T2 - An open-label study

AU - Vossler, David G.

AU - Conry, Joan A.

AU - Murphy, Jerome V.

AU - Boustany, Rose Mary

AU - Legarda, Stella

AU - Ruggles, Kevin

AU - Schachter, Steven

AU - Krishnamurthy, Kaackuzhali

AU - Sheth, Raj

AU - Vazquez, Blanca

AU - Barkley, Greg

AU - Chugani, Harry

AU - Duchowny, Michael

AU - Flamini, Robert

AU - Sirven, Joseph

AU - Uthman, Basim

AU - Wheless, James

AU - Asconape, Jorge

AU - Miller, C. Steve

AU - Pellock, John

AU - Van Orman, Cohn

AU - Filloux, Francis

PY - 2008/3

Y1 - 2008/3

N2 - Purpose. To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open-label setting. Methods. Thirty patients with refractory PME (aged ≥ 5 years), who were taking up to three antiepileptic drugs, received adjunctive zonisamide (≤ 6 mg/kg/day) therapy for 16 weeks. Myoclonic seizures were recorded daily over a 24-hour period or in 10-minute epochs in the morning, afternoon, and evening. Safety was assessed via adverse events (AEs); efficacy was measured by the percentage of patients experiencing a ≥ 50% decrease in myoclonic seizure frequency from baseline. Results. Treatment-related AEs, experienced by 53% (n = 16/30) of patients, led to five patients discontinuing zonisamide. The most common AEs were decreased appetite, somnolence, and asthenia. Overall, 36% of patients (n = 10/28) had a ≥ 50% reduction in myoclonic seizure frequency. Conclusions. These results suggest that zonisamide may be useful in the treatment of patients with PME. However, due to the size and open-label character of this study, further research is required.

AB - Purpose. To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open-label setting. Methods. Thirty patients with refractory PME (aged ≥ 5 years), who were taking up to three antiepileptic drugs, received adjunctive zonisamide (≤ 6 mg/kg/day) therapy for 16 weeks. Myoclonic seizures were recorded daily over a 24-hour period or in 10-minute epochs in the morning, afternoon, and evening. Safety was assessed via adverse events (AEs); efficacy was measured by the percentage of patients experiencing a ≥ 50% decrease in myoclonic seizure frequency from baseline. Results. Treatment-related AEs, experienced by 53% (n = 16/30) of patients, led to five patients discontinuing zonisamide. The most common AEs were decreased appetite, somnolence, and asthenia. Overall, 36% of patients (n = 10/28) had a ≥ 50% reduction in myoclonic seizure frequency. Conclusions. These results suggest that zonisamide may be useful in the treatment of patients with PME. However, due to the size and open-label character of this study, further research is required.

KW - Antiepileptic drug

KW - Myoclonic seizures

KW - Progressive myoclonic epilepsy

KW - Zonisamide

UR - http://www.scopus.com/inward/record.url?scp=41949083860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949083860&partnerID=8YFLogxK

U2 - 10.1684/epd.2008.0168

DO - 10.1684/epd.2008.0168

M3 - Article

C2 - 18367429

AN - SCOPUS:41949083860

SN - 1294-9361

VL - 10

SP - 31

EP - 34

JO - Epileptic Disorders

JF - Epileptic Disorders

IS - 1

ER -

Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: An open-label study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this